NovoCure Limited
NASDAQ:NVCR · NASDAQ Global Select
-$3.51 today
Vol 4.63M · Avg 1.52M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:NVCR · Revenue to Net Income
Key Ratios
Analysis
$674.4M of revenue converted into -$173.0M of net income for the selected period. Gross margin is 75.1% and net margin is -25.6%, showing how much revenue survives after costs and taxes. EPS is $-1.53, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $655.4M +8.3% | $605.2M +18.8% | $509.3M -5.3% | $537.8M +0.5% | $535.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $166.9M +21.6% | $137.2M +6.9% | $128.3M +11.7% | $114.9M -0.0% | $114.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $488.5M +4.4% | $468.0M +22.8% | $381.1M -9.9% | $423.0M +0.7% | $420.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 74.5% -2.8pp | 77.3% +2.5pp | 74.8% -3.8pp | 78.6% +0.1pp | 78.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $224.5M +7.1% | $209.6M -6.0% | $223.1M +8.2% | $206.1M +2.4% | $201.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $417.7M -2.6% | $428.9M +9.7% | $390.9M +27.6% | $306.4M +16.4% | $263.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $642.3M +0.6% | $638.5M +3.9% | $614.7M +19.9% | $512.5M +10.3% | $464.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $17.2M +53.1% | $11.2M +2.4% | $11.0M +3.2% | $10.6M +3.6% | $10.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$119.0M -8.6% | -$109.6M +38.2% | -$177.5M -161.4% | -$67.9M -76.9% | -$38.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -18.2% -0.1pp | -18.1% +16.7pp | -34.8% -22.2pp | -12.6% -5.4pp | -7.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$153.8M +9.8% | -$170.5M +26.8% | -$232.9M -160.1% | -$89.5M -101.9% | -$44.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -23.5% +4.7pp | -28.2% +17.5pp | -45.7% -29.1pp | -16.6% -8.4pp | -8.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $18.1M -64.5% | $51.0M +10.8% | $46.0M +191.6% | $15.8M +1339.4% | $1.1M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $11.7M +137.7% | $4.9M -39.5% | $8.1M -8.2% | $8.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $17.6M -55.4% | $39.3M -4.4% | $41.1M +435.8% | $7.7M +199.2% | -$7.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$136.3M -3.9% | -$131.2M +31.6% | -$191.7M -134.3% | -$81.8M -57.2% | -$52.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -20.8% +0.9pp | -21.7% +16.0pp | -37.6% -22.4pp | -15.2% -5.5pp | -9.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$23.0K -100.1% | $37.5M +144.8% | $15.3M +43.2% | $10.7M +70.3% | $6.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$136.2M +19.2% | -$168.6M +18.6% | -$207.0M -123.7% | -$92.5M -58.6% | -$58.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | -20.8% +7.1pp | -27.9% +12.8pp | -40.6% -23.4pp | -17.2% -6.3pp | -10.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +21.8% | -$2 +20.0% | -$2 -121.6% | -$1 -57.1% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +21.8% | -$2 +20.0% | -$2 -121.6% | -$1 -57.1% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $111.5M +3.4% | $107.8M +1.4% | $106.4M +1.7% | $104.7M +1.2% | $103.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $111.5M +3.4% | $107.8M +1.4% | $106.4M +1.7% | $104.7M +1.2% | $103.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.51B
Neogen Corporation
NASDAQ:NEOG
$1.98B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.83B
STAAR Surgical Company
NASDAQ:STAA
$1.44B
Teladoc Health, Inc.
NYSE:TDOC
$1.41B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.26B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.11B
Azenta, Inc.
NASDAQ:AZTA
$1.05B
Evotec SE
NASDAQ:EVO
$928.82M
Upstream Bio, Inc.
NASDAQ:UPB
$339.04M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NVCR generate?
NovoCure Limited (NVCR) reported $655.35M of revenue in fiscal 2025.
Is NVCR profitable?
NovoCure Limited (NVCR) reported -$136,227,000.00 of net income, with a net margin of -20.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.